Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Udvidet
  • Inability to Tolerate Standard...
  • Citér dette
  • Stav dette
  • Email dette
  • Udskriv
  • Eksportér post
    • Eksportér til RefWorks
    • Eksportér til EndNoteWeb
    • Eksportér til EndNote
  • Permanent link
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial

Show other versions (2)
Bibliografiske detaljer
Main Authors: Sive, J, Buck, G, Fielding, A, Lazarus, H, Litzow, MR, Luger, S, Marks, D, McMillan, A, Richards, S, Rowe, J, Tallman, MS, Goldstone, A
Format: Conference item
Udgivet: 2010
  • Beholdninger
  • Beskrivelse
  • Other Versions (2)
  • Lignende værker
  • Medarbejdervisning
Beskrivelse
Summary:

Lignende værker

  • Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
    af: Sive, J, et al.
    Udgivet: (2010)
  • Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
    af: Sive, J, et al.
    Udgivet: (2010)
  • Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
    af: Sive, J, et al.
    Udgivet: (2012)
  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
    af: Fielding, A, et al.
    Udgivet: (2007)
  • Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
    af: Fielding, A, et al.
    Udgivet: (2010)

Søgemuligheder

  • Søg Historie
  • Udvidet søgning

Find flere

  • Gennemse kataloget
  • Gennemse alfabetisk
  • Explore Channels
  • Kursusreservationer
  • Nye værker

Har du brug for hjælp?

  • Søgetips
  • Spørg en bibliotekar
  • FAQ’er